دورية أكاديمية
Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 transfection of guide RNA targeting on MMP9 as anti-cancer therapy in human cutaneous squamous cell carcinoma cell line A431.
| العنوان: | Clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 transfection of guide RNA targeting on MMP9 as anti-cancer therapy in human cutaneous squamous cell carcinoma cell line A431. |
|---|---|
| المؤلفون: | Teh SW; Department of Orthopaedic, Universiti Putra Malaysia, Serdang Selangor, Malaysia., Elderdery A; Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Jouf University, Saudi Arabia., Rampal S; Department of Orthopaedic, Universiti Putra Malaysia, Serdang Selangor, Malaysia., Subbiah SK; Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, India., Mok PL; Department of Biomedical Science, Universiti Putra Malaysia, Serdang Selangor, Malaysia. |
| المصدر: | Contemporary oncology (Poznan, Poland) [Contemp Oncol (Pozn)] 2023; Vol. 27 (4), pp. 255-262. Date of Electronic Publication: 2024 Feb 21. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Termedia Country of Publication: Poland NLM ID: 101233223 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1428-2526 (Print) Linking ISSN: 14282526 NLM ISO Abbreviation: Contemp Oncol (Pozn) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Poznań : Termedia |
| مستخلص: | Introduction: Cutaneous squamous cell carcinoma (SCC) is the second most common form of skin malignancy, representing around 20% of all skin cancers. It is the main cause of death due to non-melanoma skin cancer every year. Metastatic cutaneous SCC is associated with poor prognosis in patients and warrants a more effective and specific approach such as disruption of genes associated with cancer metastasis. Material and Methods: Matrix metalloproteinases (MMPs) are enzymes involved in cancer progression and are regarded as major oncotargets. Among others, MMP9 plays critical roles in tumour progression, angiogenesis, and invasion of cutaneous SCC. We aimed to determine whether the MMP9 gene is a suitable gene target for anti-cancer therapy for cutaneous SCC. We performed clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 transfection of guide RNA (gRNA) targeting the MMP9 gene into human cutaneous SCC cell line A431. Results: Following CRISPR transfection treatment, the viability ( p < 0.01) and migratory activities ( p < 0.0001) of in vitro cutaneous SCC cells were found to be reduced significantly. The use of quantitative polymerase chain reaction (qPCR) also revealed downregulation of the mRNA expression levels of cancer-promoting genes TGF- β, FGF, PI3K, VEGF-A , and vimentin . Direct inhibition of the MMP9 gene was shown to decrease survivability and metastasis of cutaneous SCC cell line A431. Conclusions: Our findings provided direct evidence that MMP9 is important in the viability, proliferation, and metastasis of cutaneous SCC cells. It serves as a positive foundation for future CRISPR-based targeted anti-cancer therapies in treating skin cancer and other forms of malignancies that involve MMPs as the key determinants. Competing Interests: The authors declare no conflict of interest. (Copyright © 2023 Termedia.) |
| References: | Anticancer Res. 2010 Oct;30(10):4177-86. (PMID: 21036738) J Am Acad Dermatol. 2018 Feb;78(2):237-247. (PMID: 29332704) J Cell Sci. 2018 Jul 30;131(14):. (PMID: 29976561) Theranostics. 2020 Apr 15;10(12):5532-5549. (PMID: 32373229) Am J Pathol. 2012 Dec;181(6):1895-9. (PMID: 23063657) Asian Pac J Cancer Prev. 2013;14(11):6245-8. (PMID: 24377512) Ann Dermatol. 2013 May;25(2):145-51. (PMID: 23717003) Br J Dermatol. 2017 Aug;177(2):373-381. (PMID: 28211039) Histopathology. 2007 Dec;51(6):793-804. (PMID: 18042068) Int J Oncol. 2017 Mar;50(3):1035-1043. (PMID: 28075447) Biochem Biophys Res Commun. 2014 Aug 8;450(4):1422-6. (PMID: 25044113) Nat Cell Biol. 2000 Oct;2(10):737-44. (PMID: 11025665) Ophthalmology. 2001 Nov;108(11):2088-98; quiz 2099-100, 2121. (PMID: 11713084) Eur J Pharmacol. 2019 May 5;850:43-52. (PMID: 30685432) Cell. 2013 May 9;153(4):910-8. (PMID: 23643243) J Nutr Biochem. 2021 Mar;89:108556. (PMID: 33249185) J Cell Biol. 2010 May 3;189(3):541-56. (PMID: 20421424) Eur J Cancer. 2006 Feb;42(3):310-8. (PMID: 16406506) J Clin Invest. 2012 Feb;122(2):464-72. (PMID: 22293185) Science. 2013 Feb 15;339(6121):823-6. (PMID: 23287722) Nat Rev Drug Discov. 2019 Sep;18(9):656. (PMID: 31477868) Oncol Rep. 2017 Jun;37(6):3565-3571. (PMID: 28498420) Cell Commun Signal. 2018 Apr 10;16(1):14. (PMID: 29636110) Exp Mol Med. 2019 Mar 25;51(3):1-11. (PMID: 30911000) PeerJ. 2019 Dec 3;7:e8182. (PMID: 31824776) Sci Rep. 2016 Dec 14;6:38834. (PMID: 27966589) |
| فهرسة مساهمة: | Keywords: CRISPR Cas9; MMP9; matrix metalloproteinase; skin cancer; targeted anti-cancer therapy |
| تواريخ الأحداث: | Date Created: 20240226 Latest Revision: 20240227 |
| رمز التحديث: | 20240227 |
| مُعرف محوري في PubMed: | PMC10883192 |
| DOI: | 10.5114/wo.2023.135364 |
| PMID: | 38405210 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!